Input 2020.12.24 06:00
For this reason, the use of approved treatments is increasing for patients with severe coronavirus who need to be administered drugs. In the first quarter of the outbreak of Corona 19 in Korea, medicines such as Immunmed and Gembax & Kael were mainly used, but since last October, the blood system of GC Green Cross has continued to dominate. Celltrion is scheduled to take additional medication after being recently named.
Corona 19 vaccines from overseas pharmaceutical companies are expected to be available only in February next year, and the timing of vaccination is uncertain, so for the time being, it is expected that applications for the use of treatments for specific patients will always be forced.
According to the Korea Drug Safety Administration on the 24th, a total of 47 cases were obtained from the Ministry of Food and Drug Safety for treatment of Corona 19 as of the 23rd.
GC has received the most approval for therapeutic use as a treatment for COVID-19 in Korea.Green Cross (006280)Blood device treatment (GC5131) Starting with Chilgok Kyungpook National University Hospital on October 19th, there are a total of 27 cases until the 23rd of this month. It accounts for more than half of the total number of approvals for COVID-19 treatment purposes in Korea.
Corona 19 patients who received GC Green Cross blood system treatment were also judged to be cured. The patient is known to have deteriorated enough to depend on a ventilator because there was no remedy even after being prescribed the antiviral drug remdesivir and the steroid drug dexamethasone. He was treated for about 20 days after receiving the blood system medication and was tested negative. It was the first case of cure after administration of a blood device.
Immunmed HzVSF v13 week was approved for use in Korea for the first time on February 21 for the treatment of Corona 19 patients. A total of eight approvals have been made, including Seoul National University Hospital, Yeungnam University Hospital, and Chungnam National University Hospital, but they have not been registered since April 10th. HzVSF v13 is a drug that was initially being developed as a treatment for influenza (flu) and hepatitis B.
Gembax (082270)Enkael’s new drug candidate GV1001 also received four approvals from April to May, but there was no later. GemVax also applied for a patent on the corona for this material in March. SCM Life Science’s stem cell therapy product’SCM-AGH’ was approved for use in a total of 3 cases in April and September, including one and two, respectively. Kangstem Biotech (217730)and Antrogen (065660), Famicel (005690)Each of these was approved. Among them, Kangstem Biotech recently received approval from the Institutional Review Board (IRB) of Seoul St. Mary’s Hospital and the Ministry of Food and Drug Safety.
Celltrion (068270)CT-P59, the COVID-19 antibody treatment under development, also received approval for its first therapeutic use at Asan Hospital in Seoul on December 11th. On the 22nd, the application at Inje University’s Sanggye Paik Hospital was also followed, and a total of two cases are being recorded.
It is observed that for the time being, domestic companies will always be forced to approve the therapeutic use of the COVID-19 treatment being developed. This is because, as the number of corona19 confirmed patients in Korea has recently increased, the number of severely ill patients who need artificial respirators or oxygen therapy are also increasing. As of this day, the number of patients with severe gastric disorders was 284 on a cumulative basis.
An official from a domestic pharmaceutical company said, “There are a number of seriously ill patients and deaths from Corona 19,” and said, “The reality is that there are no sharp measures other than the treatment companies are developing.”